Goldberg Michael sold $1.1M of CDNA
Goldberg Michael sold 13,800 shares of CareDx, Inc. (CDNA) at an average of $79.15 ($78.32–$79.85, $1.09M total) across 3 trades on 2026-11-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides transparency on insider activity but does not indicate a new operational catalyst. The pre-arranged 10b5-1 plan suggests the trades were planned in advance, reducing the informational content.
Market read
For CDNA, the main tradable takeaway is modest sentiment noise from insider selling, likely outweighed by the lack of fundamental news.
What to watch
Traders may over-weight insider sales; without accompanying changes in guidance, financing, or litigation, the fundamental signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA), reported by director Michael Goldberg.
Ticker impact
CareDx director Michael Goldberg sold 13,800 shares in an open-market transaction under a pre-arranged 10b5-1 plan, totaling about $1.09M.
Likely limited near-term impact, with any reaction more sentiment-driven than fundamentals-driven.
The filing is a primary Form 4 disclosure, but it is an open-market sale by a director executed under a pre-arranged 10b5-1 plan, which typically dampens inference about near-term company outlook.
Market effects
No clear sector read-through; this is an individual insider transaction rather than a company operating or regulatory update.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish information.
Key entities
- issuerCareDx, Inc.
Company whose director insider sale is disclosed on Form 4.
- insiderMichael Goldberg
Director who sold 13,800 shares in open-market trades under a 10b5-1 plan.



